Genetic panel aims to spot heart risk before cancer therapy begins

NCT ID NCT07663357

Recruiting now Diagnosis Sponsor: Beneficência Portuguesa de São Paulo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a genetic and epigenetic panel can predict heart damage caused by chemotherapy or immunotherapy in breast cancer patients. Researchers will analyze blood samples from 1,000 participants before and during treatment to see if certain genetic markers signal early risk. The goal is to catch potential heart problems sooner, allowing doctors to adjust treatment and protect patients' hearts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pharmacogenomic panel
What this could lead to: If successful, this could enable doctors to identify patients at high risk for heart damage before starting cancer treatment, allowing for safer, personalized therapy.
What could go wrong: This is an observational study, not a treatment trial. The genetic panel may not accurately predict cardiotoxicity in all patients, and results may not change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer Cardiotoxicity neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOTOXICITY

Contacts and locations

Locations

Complexo Hospitar HUOC/PROCAPE
NOT_YET_RECRUITING

Recife, Pernambuco, 50100-130, Brazil
FAMERP - Faculdade de Medicina de São José do Rio Preto
NOT_YET_RECRUITING

São José do Rio Preto, São Paulo, 15090-000, Brazil
Hospital BP - A Beneficência Portuguesa de São Paulo
RECRUITING

São Paulo, São Paulo, 01323-900, Brazil
Hospital Beneficente UNIMAR
NOT_YET_RECRUITING

Marília, São Paulo, 17525-160, Brazil
Instituto do Câncer do Ceará
NOT_YET_RECRUITING

Fortaleza, Ceará, 60430-230, Brazil
Universidade Federal de Santa Catarina
NOT_YET_RECRUITING

Florianópolis, Santa Catarina, 88040-900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.